Background: Interstitial lung disease (ILD) is the leading cause of mortality in systemic sclerosis (SSc) patients. Treatment options are rather limited in SSc associated ILD (SSc-ILD). Objectives: Objective of this study was to report the experience of RTX treatment in a series of patients with longstanding SSc-ILD in whom unsatisfactory response in lung functions was noted under conventional treatments. Methods: We retrospectively reviewed charts of 197 SSc patients evaluated between April 2015 and November 2016. 14 patients who received rituximab (RTX) for SSc-ILD participated in this analysis. The severity of ILD based on PFTs was defined as follows; mild (FVC between 71% and 80% of predicted), moderate (FVC between 51% and 70% of predicted) and severe (FVC ≤50%). The extent of skin disease was clinically measured by using Modified Rodnan Skin Score (mRSS) tool. End of follow-up was considered as six months after the last RTX dose. Results: Median (IQR, interquartile range) age was 53.2 (46.8-55.5) and median disease duration was 9.1 (5.1-13.6) years. Median FVC was 52.5 (41.5-64.0) prior to RTX. At the end of follow-up, no significant change was revealed in FVC when compared with pre-RTX values [58.0 (44.7-58 (Diasorin, Italy) . Pulmonary function test, chest x-ray, lung CT scan, electrocardiography, Doppler echocardiography, renal artery resistive index by eco color Doppler, Dual X-ray absorptiometry, were performed at the time of sample collection. Disease severity scale (DSS) was performed according to Medsger. Drug assumption (glucocorticoids, calcium channel blockers, cyclic intravenous iloprost, endothelin receptor antagonists) and supplementation with vitamin D analogues, were recorded. Non-parametric tests were used for statistical analysis. Results: Average 25(OH)D serum concentration was found to be 18.7±9 ng/ml (<20 classified as deficiency). A significant difference was observed among seasonal 25(OH)D serum concentration (winter: 14.6±7.8 ng/ml, spring: 17.2±7.9 ng/ml, summer 21.43±10 ng/ml, autumn 20.2±10; p=0.032) (Figure 1) . A significant correlation was found between 25(OH)D serum concentration and presence/absence of bi-basal fibrotic changes at lung computed tomography (CT) scan (average values: 16.1±8 ng/ml and 20±10 ng/ml, respectively, p=0.04). Peripheral vascular (p=0.03), kidney (p=0.02), gastrointestinal (p=0.05) Medsger's DSS parameters also were found to correlate with 25(OH)D serum concentration (Figure 1) . Interestingly, no influence of treatment with vitamin D analogues (1,000 UI daily) was found regarding 25(OH)D serum concentration in treated (18.8±10 ng/ml) and in not treated (18.7±9 ng/ml) SSc patients (p=0.81). 
Conclusions

